Rheumatoid Arthritis eJournal Club
   

The Application of New ACR Recommendations
in the Management of Rheumatoid Arthritis:
A Case Study Approach

Print this Content
 
Release Date: March 30, 2009 Renewal Date: March 30, 2010 Expiration Date: September 30, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 60 minutes
Description / Overview The purpose of this activity is to consider an initial and long-term management strategy for a patient presenting with early RA in the context of the ACR Treatment Recommendations.
Objectives On completion of this activity, participants should be able to:
  1. Recognize the value and potential of a treatment approach driven by evidence-based treatment recommendations.
  2. Discuss the key elements of the ACR Treatment Recommendations for the use of nonbiologic and biologic therapies for RA.
  3. Outline a patient management strategy for use of DMARDs or biologics in a patient presenting with early RA.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Kenneth G. Saag, MD, MSc
Professor
Departments of Medicine and Epidemiology
University of Alabama at Birmingham
Staff Physician
Clinical Immunology and Rheumatology Programs
UAB Health System/The Kirklin Clinic
Birmingham, Alabama
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty members have indicated that they may have a relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:
Leonard Calabrese, DO
  Consulting: Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Kenneth G. Saag, MD, MSc
  Consulting: Amgen Inc.; Eli Lilly and Company; Merck & Co., Inc.; Nitec Pharma GmbH; Novartis AG; Roche Laboratories, Inc.; UCB
 
  Teaching and Speaking: Eli Lilly and Company; Merck & Co., Inc.

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

CME Disclaimer